Robert C Bourge, Aaron B Waxman, Mardi Gomberg-Maitland, Shelley M Shapiro, James H Tarver, Dianne L Zwicke, Jeremy P Feldman, Murali M Chakinala, Robert P Frantz, Fernando Torres, Jeffrey Cerkvenik, Marty Morris, Melissa Thalin, Leigh Peterson, Lewis J Rubin
BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often limited by patient/physician dissatisfaction with the delivery methods. Complications associated with external pump-delivered continuous therapy include IV catheter-related bloodstream infections and subcutaneous infusion site pain. We therefore investigated a fully implantable intravascular delivery system for treprostinil infusion. METHODS: A multicenter, prospective, single-arm, clinical trial (DelIVery for Pulmonary Arterial Hypertension) was conducted by using an implantable intravascular delivery system...
July 2016: Chest